You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: second-generation antidepressants have similar effectiveness, but specific adverse effects differed

https://doi.org/10.1136/ebm.14.3.82

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    QUESTION

    What are the benefits and harms of different second-generation antidepressants?

    REVIEW SCOPE

    Included studies were randomised controlled trials (RCTs) of ⩾6 weeks’ duration that compared 1 second-generation drug with another: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, and venlafaxine. Outcomes were response rates and adverse effects.

    REVIEW METHODS

    Medline, CINAHL, EMBASE/Excerpta Medica, PsycINFO, Cochrane Central Register of Controlled Trials, International Pharmaceutical Abstracts (1980 to Apr 2007); and reference lists were searched for RCTs. Pharmaceutical manufacturers were contacted, and the Center for Drug Evaluation and Research was searched for unpublished trials. Poor-quality studies were not included unless no other direct comparison was available.

    MAIN RESULTS

    In 80 RCTs …

    View Full Text

    Footnotes

    • Source of funding: Agency for Healthcare Research and Quality.